Inicio>>Signaling Pathways>> PROTAC>>Pomalidomide-PEG1-C2-N3

Pomalidomide-PEG1-C2-N3 (Synonyms: Cereblon Ligand-Linker Conjugates 13; E3 ligase Ligand-Linker Conjugates 50)

Catalog No.GC61200

Pomalidomida-PEG1-C2-N3 es un conjugado ligando-enlazador de ligasa E3 sintetizado que incorpora el ligando cereblon basado en pomalidomida y el enlazador PEG de 1 unidad utilizado en la tecnologÍa PROTAC. Pomalidomida-PEG1-C2-N3 se puede utilizar para diseÑar un degradador selectivo CDK6 PROTAC CP-10. CP-10 induce la degradaciÓn de CDK6 con un DC50 de 2,1 nM.

Products are for research use only. Not for human use. We do not sell to patients.

Pomalidomide-PEG1-C2-N3 Chemical Structure

Cas No.: 2271036-44-1

Tamaño Precio Disponibilidad Cantidad
100mg
908,00 $
Disponible

Tel:(909) 407-4943 Email: sales@glpbio.com

Reseñas de cliente

Based on customer reviews.

  • GlpBio Citations

    GlpBio Citations
  • Bioactive Compounds Premium Provider

    Bioactive Compounds Premium Provider

Sample solution is provided at 25 µL, 10mM.

Description Chemical Properties Product Documents Related Products

Pomalidomide-PEG1-C2-N3 is a synthesized E3 ligase ligand-linker conjugate that incorporates the Pomalidomide based cereblon ligand and 1-unit PEG linker used in PROTAC technology. Pomalidomide-PEG1-C2-N3 can be used to design a selective CDK6 PROTAC degrader CP-10. CP-10 induces the degradation of CDK6 with an DC50 of 2.1 nM[1].

[1]. Su S, et al. Potent and Preferential Degradation of CDK6 via Proteolysis Targeting Chimera Degraders. J Med Chem. 2019 Aug 2.

Reseñas

Review for Pomalidomide-PEG1-C2-N3

Average Rating: 5 ★★★★★ (Based on Reviews and 27 reference(s) in Google Scholar.)

5 Star
100%
4 Star
0%
3 Star
0%
2 Star
0%
1 Star
0%
Review for Pomalidomide-PEG1-C2-N3

GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.

Required fields are marked with *

You may receive emails regarding this submission. Any emails will include the ability to opt-out of future communications.